Neuralink, Elon Musk’s brain implant company, on Thursday announced that it will begin a new clinical trial in Great Britain. The study aims to test how its chips can help patients with severe paralysis control physical and digital devices using only their thoughts.
The GB-PRIME trial will evaluate Neuralink’s fully implantable, wireless brain-computer interface, specifically the N1 Implant, in individuals with severe paralysis. It will also test Neuralink’s robotic surgical system used for precise implantation of the device.
The main goal is to empower participants to control digital as well as physical devices using only their thoughts. Positive results could pave the way for broader human trials and ultimately lead to regulatory approval. It will also transform the brain computer interface landscape.
Neuralink is partnering with Newcastle Hospitals and University College London Hospitals to conduct the study. The company stated that patients living with paralysis due to conditions like Amyotrophic Lateral Sclerosis (ALS) and spinal cord injury qualify to participate in the study.
Neuralink secured $650 million in its latest funding round last month. The company initiated human trials of its brain implant in 2024, following the resolution of safety concerns raised by the U.S. Food and Drug Administration.
Elon Musk has consistently emphasized the potential of brain-computer interfaces (BCIs) to restore communication abilities in people with neurological disorders. The company stated that five patients suffering from severe paralysis are currently using its device to control physical and digital tools using their thoughts.
“If successful, the GB-PRIME trial could mark a pivotal step toward integrating brain-computer interface technology into mainstream medical care,” said a lead analyst at Coherent Market Insights (CMI). “It will potentially transform lives by enabling greater independence and improved quality of life for individuals living with severe motor impairments.”
Expanding clinical trials in the United Kingdom may facilitate European regulatory acceptance as well as commercialization, opening a lucrative regional market for BCI solutions. If Neuralink succeeds, it could drive competition among BCI startups and medical device firms.
Positive results from the new clinical study could revolutionize the treatment approaches for neurological disease patients across Europe. It will offer new hope for patients with few treatment options.
According to Coherent Market Insights (CMI), the global brain computer interface market size is projected to reach USD 6.16 billion by 2032, up from USD 2.4 billion in 2025. This indicates that the market will grow nearly 2.5X, highlighting the increasing adoption and success of BCIs.
Global demand for brain computer interface products is poised to increase at a CAGR of 14.4% through 2032. Analysts suggest that expanding clinical trials and increased investment, particularly from players like Neuralink, are driving this growth.
Sources:
News Outlet: Reuters
